Compare MasterCard Inc (MA) vs Moderna, Inc. (MRNA) Price & Performance

Mastercard (MA) trades at $543.19, down 0.08% on the day, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $4.60 exceeding the $4.41 estimate. Revenue grew to $32.79 billion in 2025, while net income margin remained high at 45.88%. Analysts maintain a strong buy consensus with a $634.27 price target, reflecting confidence in continued payment volume growth and digital expansion initiatives.

The stock presents a compelling growth opportunity given its consistent profitability, expanding cash flows, and leadership in digital payments. Key risks include competitive disruption from stablecoins and regulatory scrutiny. With zero sell ratings and 79% buy recommendations, Wall Street sentiment is overwhelmingly positive, though investors should monitor execution on AI and emerging market strategies against valuation multiples above sector averages.

Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.

The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.